Literature DB >> 28392327

New liquid chromatography-tandem mass spectrometry method for routine TDM of vancomycin in patients with both normal and impaired renal functions and comparison with results of polarization fluoroimmunoassay in light of varying creatinine concentrations.

Hana Brozmanová1, Ivana Kacířová2, Romana Uřinovská3, Pavel Šištík3, Milan Grundmann4.   

Abstract

A new LC-MS/MS method with simple sample extraction and a relatively short period of vancomycin analysis for routine therapeutic drug monitoring was developed and validated. 50μL serum was precipitated using 20μL 33% trichloroacetic acid and 0.5mol/L NH4OH was added to increase pH before analysis. A RP BEH C18, 1.7μm, 2.1×50mm column maintained at 30°C and tobramycin as internal standard were used. Mass detection was performed in positive electrospray mode. The results obtained with LC-MS/MS method were correlated with an FPIA assay (Abbott AxSYM) using mouse monoclonal antibody. Subjects were divided into three groups according to creatinine levels (53.5±19.1, 150.2±48.4, 471.7±124.7μmol/L) and Passing-Bablok regression analysis and Bland-Altman analysis were used to compare vancomycin concentrations. The results of subjects with both normal and higher creatinine levels correlated very well and the linear regression model equations were near ideal (LC-MSVAN=0.947×AbbottVAN+0.192 and LC-MSVAN=0.973×AbbottVAN-0.411 respectively). Dialyzed patients with the highest creatinine levels showed about 14% greater vancomycin concentration with the FPIA assay (LC-MSVAN=0.866×AbbottVAN+2.127). This overestimation probably due to the presence of the metabolite CDP ought not to be of clinical relevance owing to the wide range of recommended vancomycin concentration.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Creatinine concentration; Dialyzed patients; Fluorescence polarization immunoassay; LC-MS/MS; Therapeutic drug monitoring; Vancomycin

Mesh:

Substances:

Year:  2017        PMID: 28392327     DOI: 10.1016/j.cca.2017.04.003

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

1.  Expression and 7-day time course of circulating microRNAs in septic patients treated with nephrotoxic antibiotic agents.

Authors:  Nadezda Petejova; Arnost Martinek; Josef Zadrazil; Viktor Klementa; Lenka Pribylova; Radim Bris; Marcela Kanova; Radka Sigutova; Ivana Kacirova; Zdenek Svagera; Eva Bace; David Stejskal
Journal:  BMC Nephrol       Date:  2022-03-19       Impact factor: 2.388

2.  Catalysis of electro-oxidation of antibiotics by nitroxyl radicals and the electrochemical sensing of vancomycin.

Authors:  Tetsuya Ono; Kyoko Sugiyama; Sachiko Komatsu; Masayuki Kumano; Kentaro Yoshida; Takenori Dairaku; Tsutomu Fujimura; Yusuke Sasano; Yoshiharu Iwabuchi; Yoshitomo Kashiwagi; Katsuhiko Sato
Journal:  RSC Adv       Date:  2021-06-18       Impact factor: 3.361

3.  Utility of Silver-nanoparticles for Nano-fluorimetric Determination of Vancomycin Hydrochloride in Pharmaceutical Formulation and Biological Fluids: Greenness Assessment.

Authors:  Ahmed R Mohamed
Journal:  J Fluoresc       Date:  2022-06-25       Impact factor: 2.525

Review 4.  Paper-Based Molecular-Imprinting Technology and Its Application.

Authors:  Shufang Xu; Zhigang Xu; Zhimin Liu
Journal:  Biosensors (Basel)       Date:  2022-08-03

5.  The Detection of Vancomycin in Sweat: A Next-Generation Digital Surrogate Marker for Antibiotic Tissue Penetration: A Pilot Study.

Authors:  Noé Brasier; Andreas Widmer; Michael Osthoff; Markus Mutke; Fiorangelo De Ieso; Pascale Brasier-Lutz; Kitty Brown; Linxing Yao; Corey D Broeckling; Jessica Prenni; Jens Eckstein
Journal:  Digit Biomark       Date:  2021-01-14

6.  Studies on the metabolism and degradation of vancomycin in simulated in vitro and aquatic environment by UHPLC-Triple-TOF-MS/MS.

Authors:  Mengsi Cao; Yanru Feng; Yan Zhang; Weijun Kang; Kaoqi Lian; Lianfeng Ai
Journal:  Sci Rep       Date:  2018-10-19       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.